{"filing":{"accession_number":"0001778016-26-000005","cik":"0001778016","ticker":"NBP","company_name":"NovaBridge Biosciences","form":"6-K","filing_date":"2026-06-16","report_date":null,"primary_document":"nbp_-_6-k_-_change_of_au.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1778016/000177801626000005/nbp_-_6-k_-_change_of_au.htm"},"events":[{"id":12383,"run_id":10952,"accession_number":"0001778016-26-000005","anchor_item_number":null,"event_type":"auditor_change","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"The 6-K discloses the dismissal of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm effective immediately on June 16, 2026, and the concurrent appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP as the new auditor. This is a classic auditor change event. The filing explicitly states there were no disagreements on accounting principles or practices, and the only reportable events were pre-existing material weaknesses in IT general controls previously disclosed in the Company's Form 20-F filings, which mitigates but does not eliminate the materiality of the auditor transition itself.","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-06-16","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":9209,"accession_number":"0001778016-26-000005","item_number":null,"item_title":null,"event_type":"auditor_change","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"The 6-K discloses the dismissal of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm effective immediately on June 16, 2026, and the concurrent appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP as the new auditor. This is a classic auditor change event. The filing explicitly states there were no disagreements on accounting principles or practices, and the only reportable events were pre-existing material weaknesses in IT general controls previously disclosed in the Company's Form 20-F filings, which mitigates but does not eliminate the materiality of the auditor transition itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:41:46.154832+00:00","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-06-16"}]}